Trial
NCT05928806
Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
Phase IISUSPENDEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Michael B. Atkins, MD
Collaborators
Agenus Inc.; Georgetown University
Condition
Advanced Renal Cell Carcinoma
Intervention
Botensilimab
Why stopped
Interim Analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-11